Change of plasma transforming growth factor-β1 levels in nasopharyngeal carcinoma patients treated with concurrent chemo-radiotherapy

Japanese Journal of Clinical Oncology

Volumn 35, Issue 8, 2005, Pages 427-432

  Chen, Hong Wen ^a,b   Chang, Yue Cune ^c   Lai, Yuen Liang ^b   Chen, Yu Jen ^b   Huang, Ming Jer ^b   Leu, Yi Shing ^b   Fu, Ying Kai ^d   Wang, Ling Wei ^e   Hwang, Jeng Jong ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c TAMKANG UNIVERSITY   (Taiwan)

^d INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Concurrent chemo radiotherapy; Nasopharyngeal carcinoma; Transforming growth factor 1 (TGF 1)

Indexed keywords

CISPLATIN; FLUOROURACIL; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DERMATITIS; DRUG DOSE REGIMEN; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MORBIDITY; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; PROTEIN BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DERMATITIS; HUMANS; MOUTH MUCOSA; NASOPHARYNGEAL NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; STOMATITIS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 24944444439     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyi126     Document Type: Article

References (38)

1. Annual Report of Cancer Registration System, Department of Health, Taiwan, 2000.
2. Perez CA, Brady LW. Nasopharynx. Principles and Practice of Radiation Oncology. Vol. XXXV, 3rd edn. Philadelphia Lippincott-Raven; 1997.
3. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
4. Lyman JT, Wolbarst AB. Optimization of radiation therapy III: A method of assessing complication probabilities from dose-volume histograms. Int J Radiat Oncol Biol Phys 1987;113:103-9.
5. Finkelstein JN, Johnston CJ, Baggs R, Rubin P. Early alterations in extracellular matrix and transforming growth factor β gene expression in mouse lung indicative of late radiation fibrosis. Int J Radiat Oncol Biol Phys 1994;28:621-31.
6. Anscher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998;41:1029-35.
7. Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, et al. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:988-95.
8. Kong FM, Anscher MS, Jirtle RL. Transforming growth factor beta. Methods Mol Biol 1997;20:1-15.
9. Xu J, Menezes J, Prasad U, Ali A. Elevated serum levels of transforming growth factor β1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer 1999;84:396-9.
10. Danielpour D. Improved sandwich enzyme-linked immunosorbent assays for transforming growth factor beta 1. J Immunol Methods 1993; 158:17-25.
11. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
12. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
13. Rifkin DB. Latent transforming growth factor-β binding proteins: orchestrators of TGF-β availability. J Biol Chem 2005;280:7409-12.
14. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
15. Roberts AB. Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 1998;24:111-9.
16. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nature Genet 2001;29:117-29.
17. Massague J, Blain SW, Lo RS. TGF-β signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
18. Wakefield L, Roberts AB. TGF-β signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12:22-9.
19. Reiss M. Transforming growth factor-beta and cancer: A love hate relationship? Oncol Res 1997;9:447-57.
20. Ebner R, Chen RH, Lawler S, Zioncheck T, Derynck R. Determination of type I receptor specificity by the type II receptors for TGF-beta or activin. Science 1993;262:900-2.
21. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, Ivanisevic-Milovanovic O, et al. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: Association with disease progression. Euro J Cancer 2003;39:454-61.
22. Murase T, Jirtle RL, McDonald GB. Transforming growth factor-beta plasma concentrations in patients with leukemia and lymphoma receiving chemoradiotherapy and marrow transplantation. Blood 1994;83:2383.
23. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, et al. Preoperative plasma levels of transforming growth factor beta1 strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19:2856-64.
24. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, et al. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma: Comparison with chronic liver disease. Cancer 1994;73:2269-75.
25. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995;222:155-62.
26. Ahmad A, Menezes J. Binding of the Epstein-Barr virus to human platelets causes the release of transforming growth factor-beta. J Immunol 1997;159:3984-8.
27. Cayrol C, Flemington EK. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: Activation of transforming growth factor beta igh3 (TGF-beta igh3) and TGF-beta 1. J Virol 1995;69:4206-12.
28. Stavnezer J. Regulation of antibody production and class switching by TGF-beta. J Immunol 1995;155:1647-51.
29. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/ insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995;10:1725-9.
30. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 1994;91:6002-6.
31. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
32. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-β1. Mol Endocrinol 1996;10:1077-83.
33. Ehrhart EJ, Carroll A, Segarini P, Tsang M LS, Barcellos-Hoff MH. Latent transforming growth factor-β activation in situ: Quantitative and functional evidence following low dose irradiation. FASEB J 1997;11: 991-1002.
34. Ewan KB, Henshall-Powell RL, Ravani SA, Pajares MJ, Arteaga C, Warters R, et al. Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res 2002;62:5627-31.
35. Ohmori T, Yang JL, Price JO and Arteaga CL. Blockade of tumor cell transforming growth factor-βs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp Cell Res 1998;245:350-9.
36. Yamada H, Vijayachandra K, Penner C, Glick A. Increased sensitivity of transforming growth factor (TGF) β1 null cells to alkylating agents reveals a novel link between TGFβ signaling and O6-methylguanine methyltransferase promoter hypermethylation. J Biol Chem 2001; 276:19052-8.
37. Clark DA, Coker R. Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol 1998;30:293-8.
38. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: The dark side of tissue repair. J Clin Invest 1992;90:1-7.